Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBITDA (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed EBITDA for 12 consecutive years, with -$39.2 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA fell 121.68% year-over-year to -$39.2 million; the TTM value through Mar 2026 reached -$151.8 million, down 296.32%, while the annual FY2025 figure was -$130.3 million, 68.19% down from the prior year.
  • EBITDA hit -$39.2 million in Q1 2026 for Cartesian Therapeutics, up from -$92.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $28.7 million in Q1 2022 and bottomed at -$177.6 million in Q4 2023.
  • Average EBITDA over 5 years is -$25.4 million, with a median of -$11.4 million recorded in 2023.
  • Year-over-year, EBITDA plummeted 3128.85% in 2023 and then skyrocketed 221.34% in 2024.
  • Cartesian Therapeutics' EBITDA stood at $5.9 million in 2022, then tumbled by 3128.85% to -$177.6 million in 2023, then skyrocketed by 94.22% to -$10.3 million in 2024, then crashed by 801.49% to -$92.6 million in 2025, then soared by 57.66% to -$39.2 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$39.2 million, -$92.6 million, and -$35.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.